

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Finerenone

March 17, 2026

Therapeutic category

Other cardiovascular agents

Non-proprietary name

Finerenone

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, posaconazole, voriconazole, preparations containing ritonavir, darunavir, fosamprenavir, preparations containing cobicistat, clarithromycin, ensitrelvir, lonafarnib			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Itraconazole, posaconazole, voriconazole, preparations containing ritonavir, darunavir, fosamprenavir, preparations containing cobicistat, clarithromycin, ensitrelvir, lonafarnib, <u>ceritinib</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Itraconazole Posaconazole Voriconazole Preparations containing ritonavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir Lonafarnib	The blood concentration of finerenone may markedly increase.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.	Itraconazole Posaconazole Voriconazole Preparations containing ritonavir Darunavir Fosamprenavir Preparations containing cobicistat Clarithromycin Ensitrelvir Lonafarnib <u>Ceritinib</u>	The blood concentration of finerenone may markedly increase.	The clearance of finerenone is decreased by the potent inhibition of CYP3A.